Get the Stockscreener App
30.75
0.65%
-0.20
After Hours:
30.83
0.08
+0.26%
Royalty Pharma Plc stock is traded at $30.75, with a volume of 2.87M.
It is down -0.65% in the last 24 hours and up +22.41% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$30.95
Open:
$30.72
24h Volume:
2.87M
Relative Volume:
0.97
Market Cap:
$13.66B
Revenue:
$2.27B
Net Income/Loss:
$1.15B
P/E Ratio:
12.06
EPS:
2.55
Net Cash Flow:
$2.80B
1W Performance:
+4.27%
1M Performance:
+22.41%
6M Performance:
+9.43%
1Y Performance:
+8.54%
1-Day Range:
$30.52
$31.08
1-Week Range:
$29.67
$31.09
52-Week Range:
$24.05
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
30.75 | 13.66B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know - Yahoo Finance
Overbrook Management Corp Has $3.02 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Ascendis and Royalty Pharma enter into $150M royalty funding agreement - MSN
Where are the Opportunities in (RPRX) - Stock Traders Daily
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
Royalty Pharma: Key Strategic Updates To Be Priced In - Seeking Alpha
Investors Purchase High Volume of Royalty Pharma Call Options (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (RPRX) 2900 contracts of July 32.50 calls trade - StreetInsider.com
Royalty Pharma simplifies corporate structure with $1.1 billion deal -January 10, 2025 at 07:51 am EST - Marketscreener.com
Pallas Capital Advisors LLC Invests $2.36 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22 - Simply Wall St
Royalty Pharma (NASDAQ:RPRX) Has Announced That It Will Be Increasing Its Dividend To $0.22 - Yahoo Finance
Nordea Investment Management AB Decreases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc authorizes a Buyback Plan. - Marketscreener.com
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher? - MSN
Here’s Why Royalty Pharma plc (RPRX) Led This Week’s Rally - Insider Monkey
These 10 Firms Led This Week’s Rally - Insider Monkey
Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus PT from Analysts - MarketBeat
Royalty Pharma’s Strategic Moves and Share Buyback Plan - MSN
10 Firms Close Shortened Trading Week Higher - Insider Monkey
Royalty Pharma plc (NASDAQ:RPRX) Declares Quarterly Dividend of $0.22 - MarketBeat
Royalty Pharma Breaks Above 200-Day Moving AverageBullish for RPRX - Nasdaq
Big Corporate Moves: Acquisitions And Sales Reshape Industries - Finimize
Royalty Pharma (NASDAQ:RPRX) Shares Gap UpHere's What Happened - MarketBeat
Royalty Pharma to acquire manager, announce buyback program By Investing.com - Investing.com Australia
Royalty Pharma stock rises following RP Management buyout and $3 billion buyback plan - Investing.com Nigeria
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
Royalty Pharma to acquire manager, announce buyback program - Investing.com India
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program - The Manila Times
Royalty Pharma Hits Record $2.8B in Deals, Projects $1.2B Peak Pipeline Royalties - StockTitan
Royalty Pharma (RPRX) Announces Acquisition of its External Manager and $3 Billion Share Repurchase Program - StreetInsider.com
Royalty Pharma Unveils $3B Buyback Plan, Projects $1.6B Savings from Manager Acquisition - StockTitan
Royalty Pharma Announces Dividend Increase - The Manila Times
Royalty Pharma Boosts Quarterly Dividend by 5% to $0.22 Per Share, Payable March 2025 - StockTitan
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by JPMorgan Chase & Co. - MarketBeat
JPMorgan Chase & Co. Sells 6,449,863 Shares of Royalty Pharma plc (NASDAQ:RPRX) - Defense World
(RPRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Principal Financial Group Inc. Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Looking For Yields: Comcast, Royalty Pharma And Regions Financial Are Consistent Moneymakers - Benzinga
(RPRX) Trading Advice - Stock Traders Daily
Jim Cramer on Royalty Pharma plc (RPRX): ‘Disappointing Stock, Man, I Can’t Believe It’ - Insider Monkey
Jim Cramer Talked About These 8 Stocks - Insider Monkey
Possible Bearish Signals With Royalty Pharma Insiders Disposing Stock - Simply Wall St
Royalty Pharma (NASDAQ:RPRX) Rating Increased to Strong-Buy at TD Cowen - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):